These results agree with those of Prapiska et al., where they observed in 33 patients with penile carcinoma that the 3-year survival was 18% in those patients with high p53 expression, while it was 60% in those with low p53 expression, demonstrating its utility as a prognostic factor [40]. This evidence concerns the gene TP53 and penile carcinoma.